Alembic Pharma gains on getting USFDA's tentative approval for Dabigatran Etexilate Capsules

10 Jul 2017 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 520.45, up by 5.10 points or 0.99% from its previous closing of Rs. 515.35 on the BSE.

The scrip opened at Rs. 510.00 and has touched a high and low of Rs. 521.00 and Rs. 510.00 respectively. So far 1741 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 709.30 on 23-Mar-2017 and a 52 week low of Rs. 492.25 on 27-Jun-2017.

Last one week high and low of the scrip stood at Rs. 529.95 and Rs. 497.25 respectively. The current market cap of the company is Rs. 9811.31 crore.

The promoters holding in the company stood at 72.68%, while institutions and non-institutions held 14.00% and 13.32% respectively.

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dabigatran Etexilate Capsules, 150 mg. Dabigatran Etexilate Capsules, 150 mg have an estimated market size of $726.3 million for twelve months ending December 2016. The company now has a total of 60 ANDA approvals (52 final approvals and 8 tentative approvals) from USFDA.

The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) PRADAXAO Dabigatran Etexilate Mesylate Capsules, Eq to 150 mg base, Boehringer Ingelheim. Dabigatran Etexilate Capsules are indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5 to 10 days. It is also indicated to reduce the risk of recurrence of DVT and PE in patients who have been previously treated.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.

Alembic Pharma Share Price

852.30 -4.95 (-0.58%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×